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Abstract Background: Assessment of testosterone undeca-
noate’s (TU) presence in the functional compartments of the
male reproductive tract has never been performed despite the
evidence that its documented beneficial effect in male
infertility might be mediated through an epididymal action
and this study was set to examine this possibility.
Materials and methods: In 18 normozoospermic volunteers
TU has been administered (40 mg t.i.d.) for 6 days with
serum measurements of TU, total testosterone (T), DHT, E2,
SHBG, FSH, LH, and PRL before and at the end of
medication. Steroid hormones (T, E2, and TU) were also
assayed in seminal plasma. In a selected group of 7 men with
previously diagnosed non-obstructive azoospermia TU, T,
and E2 were assayed in the extracts of testicular biopsy
material taken before ICSI and at the end of the same
medication.
Results: A marked rise of serum DHT (average 148%,
P < 0.001) has been found after treatment, whereas T, E2,
FSH, LH, SHBG, and PRL did not significantly change.
Measurable amounts of TUwere found in the serum of all men
but only in 6 cases in seminal plasma (11.1 ± 8.0 ng/mL) and
all of them in semen delivered 7-8 h after the last TU capsule
was taken. In dilution fluid from testicular tissue extracts, no
detectable amounts of TUwere found whereas mean values of
92.5 ± 54.3 pg/mL and 43.8 ± 16.3 ng/mL for E2 and T
were observed. Positive correlations among TU and E2, T or
DHT concentrations were found in serum samples (P < 0.01,
0.02, and 0.002) as well as between E2 and T (P < 0.01), E2
and DHT (P < 0.001), or T and DHT (P < 0.001).
Conclusion: It is concluded that TU was identified and
measured for the first time in seminal plasma of a fair
percentage (33%) of men on this medication and was
associated in all men with a marked rise of DHT
concentration, a known epididymal function promoter, in
the absence of an effect on pituitary and gonadal activity. On
this evidence, it appears that a beneficial effect of TU on
epididymal function may be a distinct possibility.
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Résumé L’évaluation de la présence d’undécanoate de
testostérone (TU) dans les compartiments fonctionnels de
l’appareil reproducteur masculin n’a jamais été réalisée
malgré le fait que son effet bénéfique documenté dans
l’infertilité masculine pourrait être médié par une action
épididymaire; cette étude avait comme but d’examiner cette
possibilité.
Chez 18 volontaires normozoospermiques, du TU a été
administré (40 mg 3x/j) pendant 6 jours avec des dosages
sériques de TU, testostérone totale (T), DHT, E2, SHBG,
FSH, LH et PRL avant et à la fin du traitement. Les hormones
stéroïdes (T, E2, TU) ont également été mesurées dans le
plasma séminal. Dans un groupe de 7 hommes ayant une
azoospermie non obstructive préalablement diagnostiquée,
les concentrations de TU, T et E2 ont été mesurées dans des
fragments de tissu de la biopsie testiculaire effectuée avant
ICSI et à la fin du même traitement.
Une augmentation marquée des taux sériques de DHT
(moyenne de 148 %, P < 0,001) a été retrouvée après le
traitement alors que T, E2, FSH, LH, PRL SHBG n’ont pas
sensiblement changé. Des quantités mesurables de TU ont
été retrouvées dans le sérum de tous les hommes, mais pour
E. Koukkou (*) · G. Mitios · N. Kapolla · A. Pappa ·
S. Nicopoulou · D. A. Adamopoulos
Department of Endocrinology, Diabetes and Metabolism,
Elena Venizelou Hospital, 2E Venizelou Square,
Athens GR-11521, Greece
e-mail : hel-soc-andro@ath.forthnet.gr
E. Spiropoulos · M. Bourounis
Department of Urology, Navy Hospital, Athens GR-11521, Greece
H. Lass
NV Organon, 5340 BH Oss, The Netherlands
six cas seulement dans le plasma séminal (11.1 ± 8.0 ng/mL)
et pour l’ensemble d’entre eux, dans le sperme recueilli 7-
8 heures après la prise de la dernière gélule de TU. Dans le
liquide de dilution des fragments de tissu testiculaire, ont été
retrouvées des quantités non détectables de TU, tandis que
les valeurs moyennes pour les concentrations de E2 et T ont
été évaluées à 92.5 ± 54.3 pg/mL et 43.8 ± 16.3 ng/mL.
Des corrélations positives entre les concentrations de TU et
E2, T ou DHT ont été retrouvées dans les échantillons de
sérum (P < 0.01, 0.02 et 0.002), ainsi que entre E2 et T
(P < 0.01) ou E2 et DHT (P < 0.001) ou T et DHT
(P < 0.001).
Il est conclu que du TU a été identifié et mesuré pour la
première fois dans le plasma séminal d’un pourcentage
considérable (33 %) des hommes prenant ce traitement et sa
présence a été associée pour tous les hommes à une hausse
marquée de la concentration de DHT, un promoteur de la
fonction épididymaire, en l’absence d’un effet sur l’activité
de l’hypophyse et des gonades. Sur cette base, apparaît
légitime de retenir un possible effet bénéfique du TU sur la
fonction épididymaire.
Mots clésUndécanoate de testostérone · Dihydrotestostérone ·
Plasma séminal · Sang périphérique
Introduction
The effects of testosterone undecanoate (TU) on pituitary and
testicular basal or stimulated hormone secretion have been
studied in detail and no compromising actions of its
administration have been demonstrated at a dose of
120 mg/day [1-3]. Moreover, TU administration as an
auxiliary of tamoxifen citrate therapy in patients with
idiopathic oligozoospermia (I.O.) has resulted in a significant
improvement of sperm parameters and a marked increase of
the functional sperm fraction. Additionally, this combination
significantly increased the number of pregnancies in
subfertile couples with male factor problem related to
I.O. [4].
The beneficial effect of TU on sperm parameters has been
attributed to the action of this agent mainly on accessory
glands since direct effects of TU either on Leydig cells or on
seminiferous tubules have not been convincingly demon-
strated. In this regard, it would be of interest to seek evidence
for TU’s presence in the different compartments and
biological fluids of the male reproductive tract.
This piece of work was designed to investigate the
possibility of TU’s presence in the various compartments of
the male genital apparatus and particularly those responsible
for spermatogenesis and sperm maturation these including
seminal fluid and testicular tissue. Moreover, the effects of
TU on the main biological promoter of accessory glands,
dihydrotestosterone (DHT), were also evaluated.
Clinical material and methods
Patients
A total of 18 healthy men, aged 22-58 years, volunteered for
this study. The protocol included the following steps
(Table 1): (a) initial evaluation with sperm analysis and
hormone assessment, (b) administration of TU (40 mg in
castor oil capsules taken immediately before meals, t.i.d.) for
6 days, and (c) final evaluation on day 7 of treatment in a
manner similar to that of the initial assessment. Time of
sample collection was 08.00-10.00 with sperm delivery
following blood sampling by an average of less than 1 h and
7-8 h after the last TU capsule was taken. In a small number
of cases (4) ejaculation on final evaluation occurred 3-4 h
after the last TU capsule, whereas in the remaining volunteers
the seminal samples were collected some 7-8 h after the last
dose of medication was taken.
In an unrelated group of 7 cases with previously
established non-obstructive azoospermia who were similarly
treated with TU, testicular sperm extraction procedures took
place in the context of an ICSI procedure 7-8 h after the test
TU capsule (08.00-10.00) and tissue samples were kept
frozen until evaluation.
Endocrine evaluation included measurements of FSH,
LH, PRL, total testosterone (T), estradiol (E2), DHT, SHBG
and TU in blood samples, T, E2 and TU in seminal plasma
specimens and the same steroids in post-TU testicular tissue
(all morning samples). In the latter cases, tissue samples after
homogenization and extraction were kept frozen at −20°C
Table 1 Protocol of the study
I. Initial evaluation
hormone assays
peripheral blood: FSH, LH, PRL, T, DHT, E2, SHBG
seminal fluid: T, TU, E2
sperm collection
#
II. TU 40 mg t.i.d. x 6 days
#
III. Final evaluation (7th day)
hormone assays
peripheral blood: FSH, LH, PRL, T, DHT, TU, E2, SHBG
seminal fluid: T, TU, E2
sperm collection*
* sperm collection after the last dose: 3-4 hours (n:4) or 7-8 hours
(n:14)
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and after defrosting they were weighted and freezed in N2.
Extraction with 5 mL of diethylether for 2 min and
centrifugation for 10 min at 1200 × g were the next steps
and the ether extracts were dried under air. Lastly, 0.5 mL of
phosphate buffer was added to the dried extract of each
sample before the RIA assays. Due to a laboratory
mishappening, seminal plasma specimens for DHT assess-
ment were destroyed.
The protocol of the study has been formulated in
accordance to Helsinki’s declaration of 1995 as modified in
2000 and was pre-registered according to the appropriate
guidelines [5]. Moreover, the protocol proposed has
been approved by both Hospitals Ethics and Research
Committee.
All volunteers have been properly informed for the
purpose of the study and the procedure involved and gave
their written and informed consent.
Methods
Sperm analysis was carried out before and at the end of TU
treatment following the WHO criteria [6].
Assays of FSH, LH, PRL, E2, and SHBGwere made using
AutoDelphia kits B017-201, B031-101, B018-301, B056-
101, and B070-101, respectively (PerkinElmer, Inc., Wallac
Dy, Turku-Finland). The standards for FSH–LH have been
calibrated against the 2nd IRP of pituitary FSH/LH for
human bioassay (78/549) and for PRL against WHO 3rd
International Standard for Prolactin (coded 84/500). Assays
for T and DHT were made by resident assays employing
capillary gas chromatography with mass spectrometry using
positive ion chemical ionization and applying ammonia as
reaction gas in multiple ion detection (MID) mode. In this
MID mode, the trimethylsilane (TMS) derivative of T was
measured at m/z 361.2, the TMS derivative of DHT was
measured at m/z 363.2, the TMS derivative of deuterated T
was measured at m/z 364.2, and the TMS derivative of DHT
was measured at m/z 366.2.
GC–MS analysis was done on a HP 5890 series II Gas
Chromatograph (Agilent Technologies, Netherlands B.V.)
equipped with a CTCAutosampler (CTCAnalytics), a fused-
silica capillary column [(DB-17, length = 20 m, ID =
0.18 mm, film-thickness = 0.30 μm (J&W Scientific)], and
connected to a Finnigan MAT TSQ 7000 mass spectrometer.
Inter-assay and intra-assay variation coefficients for T were
6.4% and 7.2%, respectively, the corresponding figures for
DHT being 7.2% and 3.7%.
TU and its internal standard ([2H3]-TU 538) were isolated
from human serum and seminal plasma by solid phase
extraction. The extracts were quantified by liquid chroma-
tography coupled to mass spectrometry (LC–MS) using
electrospray ionization in multi-reaction monitoring (MRM)
mode. In the MS/MS mode the protonated [M+H]+
molecules of TU and [2H3]-TU are used as precursor ion
and measured as product ion atm/m 270.0 andm/z 273 [small
deviations in the masses (m/z ± 0.2) may occur due to tuning
differences].
LC–MS analysis was done on a HP 1100 (Applied
Biosystems) equipped with a CTC Autosampler (CTC
Analytics), an analytical column (Supelcosil LC-8-DB,
length = 50 mm, ID = 4.6 mm, particle size = 5 μm), and
connected to an Applied Biosystems API 3000 mass
spectrometer. TU in serum: Inter-assay precision was
<10.0% (taken from assay validation) and intra-assay
precision was <11.9% (taken from ba study).
Inter- and intra-assay coefficients of variation for FSH
were 3.3% and 1.7%, for LH 5.7% and 2.6%, for PRL 6.3%
and 4.2%, for E2 8.1% and 5.4%, and for SHBG 8.8% and
2.8%, respectively.
Statistics
Analysis of the data was carried out using Mediscale and
Excel statistical programs. Sperm data were expressed as
median (25th, 75th percentiles), whereas hormone values as
mean ± SD.
Results
Sperm analysis results were all within the normal range for
the group of normozoospermic volunteers (median – 25th,
75th percentile: 116.1 total cells × 106/mL – 56.2, 213.4)
and showed no marked variation as a result of TU treatment
(140.2 total cells × 106 mL – 39.1, 221.7).
Regarding the hormonal measurements the results were as
follows.
Peripheral blood
TU was found in measurable amounts in peripheral blood
while on medication in concentrations relatively higher than
those of T (Table 2). On the other hand, DHT showed a
remarkable rise following TU treatment (average 148%,
P < 0.001), whereas T and E2 showed non-significant
changes as a result of this medication. With regard to the
pituitary hormones, FSH, LH, and PRL showed no
significant variations as a result of this treatment (Table 2).
Moreover, SHBG remained also unchanged, signifying the
lack of a marked effect of TU on its regulation as expected
since E2 levels did not change either.
Evaluation of the relationships among the hormonal
parameters studied showed positive correlations between
TU and E2, T or DHT (P < 0.01, 0.02, and 0.002) in
peripheral blood while on treatment. Moreover, significant
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inter-relationships between serum E2 and T (P < 0.01) or
DHT (P < 0.001) and T and DHT (P < 0.001) were also
noted.
Seminal plasma
The concentration of T and E2 in seminal plasma showed little
variation in the subgroups studied (Table 3).On the other hand,
TU was variable being below the sensitivity of the method in
most samples but measurable in 6 cases, coming from the
subgroup of sperm delivery 7-8 h after taking the last TU
capsule. Of interest was the finding that higher serum
TU values were noted in men with measurable amounts of
this agent in seminal plasma than in those with undetectable
levels (13.8 ± 2.1 ng/mL n = 6 vs 11.6 ± 1.4 n = 12,
P < 0.05). On the other hand, serum TU values in men with
short or long time of ejaculation from the last TUcapsule (3-4 h
vs 7-8 h)were not different (13.2 ± 1.7 vs 12.1 ± 1.3 ng/mL).
The ratio of blood to seminal plasma concentrations was
not different in the 3 subgroups after TU treatment (for T, a:
6.2 ± 1.3, b: 6.7 ± 2.3, and c: 5.8 ± 2.7; for E2, a: 0.39 ± 13,
b: 0.36 ± 21, and c: 0.37 ± 19). In the case of TU, the
concentration ratio between the two biological fluids was
1.14 ± 0.36 in those men with detectable levels in seminal
plasma (subgroup c), this being indicative of the relatively
higher presence of TU in the latter fluid. No marked changes
as a result of TU administration were noted for T and E2
levels.
Testicular tissue
Determination of E2, T, and TU in dilution fluid from
testicular tissue extracts showed mean values of
92.5 ± 54.3 pg/mL for E2, 43.8 ± 16.3 ng/mL for T but no
detectable TU levels (<0.01 ng/mL).
Discussion
The present study has elucidated to a certain degree the ways
by which TU exerts its effect on the functional ability of some
important compartments of the male reproductive tract and,
indirectly, on sperm quality in man. To start with, TU was
detected in a number of seminal plasma samples in
concentrations comparable to those of peripheral blood.
This finding was indicative of the ability of this lipophilic
androgen to find its way through circulation into the
biological fluids contained in the ejaculation. Obviously, a
uniform pattern of TU’s presence in the seminal plasma
could not be demonstrated but only in part of the cases and
this, theoretically, might have been related to factors like
poor absorption of the compound, unknown clearance
conditions in the reproductive tract, local tissue pathology
or faulty compliance. Certainly, the higher serum TU values
seen in men with measurable than those with undetectable in
seminal plasma TU levels might have been a contributing,
although not decisive, factor. On the other hand, the fact that
TU was not detected in seminal samples ejaculated shortly
after taking the medication (3-4 h) may be indicative of the
time needed for this agent to find its way into the relevant
biological fluid. Other parameters determining the specific
pharmacokinetics of TU may have been also involved in
bringing about the presence or absence of this agent from
seminal plasma. In the same context, it was of interest that
TU was not detected in testicular tissue extracts indicating
that no appreciable part of this androgen was present, mostly,
in seminiferous tubules. The precise reason for this failure
cannot be postulated and factors like methodology might
have been involved. However, as an implication of the
negative finding, it follows that the seminal plasma TU












4.9 ± 1.6+ 0.46 ± 0.20 27.6 ± 8.0 not assayed
on-TU
n:18












6.0 ± 0.7 5.0 ± 2.0 5.1 ± 3.7 30.0 ± 13.8
on-TU
n:18
5.1 ± 2.5 4.0 ± 2.0 4.1 ± 2.1 26.0 ± 1.7
+ mean ± SD, * difference from pre-TU: P < 0.001








a. 0.54 ± 0.26× not assayed 68.2 ± 23.2
b. 0.62 ± 0.29 not assayed 75.1 ± 28.3
c. 0.63 ± 0.34 not assayed 72.2 ± 30.4
on-TU
a. 0.64 ± 0.25 <0.1* 67.0 ± 33.3
b. 0.68 ± 0.33 <0.1** 72.1 ± 19.0
c. 0.73 ± 0.32 11.1 ± 8.0+ 70.7 ± 21.0
× mean ± SD.
* undetectable, 3-4 hours after last TU capsule (n:4).
** undetectable, 7-8 hours after last TU capsule (n:8).
+ detectable, 7-8 hours after last TU capsule (n:6).
200 Androl. (2009) 19:197-202
measured in the relevant subgroup was probably not of
testicular origin.
Of importance was also the observation that the peripheral
blood to seminal plasma concentration ratio in those cases
with simultaneous presence of TU in both fluids was close to
one (1.14 ± 0.36). Indeed, it appears that the average TU
concentration in the positive seminal fluid samples was
approximately 87.4% of that of peripheral blood, this being
indicative of a very active transfer mechanism of this agent
from circulation to this fluid product of the genital system. In
such conditions one may speculate for TU’s entrance also in
other compartments of the tract including epidydimis. This
part of the tract is particularly active in promoting sperm
maturation [7] and its functional activity is mostly DHT-
dependent [8,9]. Unfortunately, the failure to demonstrate the
presence of TU in all seminal samples obscures the picture.
An important finding of this study was the rise of blood
DHT following TU treatment. This was a very marked
change (147.8% rise) and, probably, biologically significant
in affecting accessory gland function and thus improving
sperm quality. Indeed, although DHT’s effects on human
spermatogenesis are not clearly established [10-13], on the
other hand it is well known that these androgen exerts
important biological actions on accessory gland function and
particularly epididymis [14] and, therefore, a beneficial effect
on sperm parameters can be anticipated in oligozoospermic
men on treatment with the combination of TU and tamoxifen
citrate (TMX). Indeed, marked improvements of acrosine,
aniline, and free l-carnitine levels were noted in a properly
designed trial [3]. In this context, it was unfortunate that DHT
measurements in seminal plasma were not available.
However, evidence from other studies indicates that this
steroid is present in measurable amounts in this fluid [15-18].
Moreover, earlier studies had demonstrated an increase of
peripheral plasma DHT following TU administration in
dyspermic men [19]. In this context, our data lend support to
those findings and substantiate the hypothesis for a biological
effect of this hormone at epididymal level.
Finally, regarding the lack of an effect on pituitary activity
and particularly on LH, this was to be expected since earlier
studies have shown that short-term TU administration at the
dosage employed did not compromise basal gonadotropin
secretion [2], whereas the absence of an effect on SHBG was
probably related to the short duration of treatment as well as
the lack of any T and E2 changes.
By and large, it appears that TU administration in addition
to its presence in seminal fluid amplifies the bioavailability of
DHT in peripheral blood and hence in accessory glands.
These observations are of great relevance for men treated
with TU and TMX for I.O., a sperm abnormality very often
associated with a compromised androgen bioactivity [15, 20].
Moreover, these findings advance the understanding of
complimentary actions of TMX and TU in the empiric
management of I.O. with this combination. It appears that
TU’s contribution is probably exerted through its augmenting
effect on androgen bioactivity at epidydimal and accessory
glands level thus improving the local environment and sperm
maturation.
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